Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

32.72
+0.28570.88%
Post-market: 32.720.00000.00%16:10 EDT
Volume:2K
Turnover:74.53K
Market Cap:41.71M
PE:- -
High:32.81
Open:32.81
Low:32.72
Close:32.43
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:0.61
T/O Rate:0.18%
Dividend:0.08
Dividend Rate:0.23%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Oct 03

Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says

MT Newswires Live
·
Oct 03

Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Legend Biotech (LEGN)

TIPRANKS
·
Oct 02

Correction: Top Midday Decliners

MT Newswires Live
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

More Upside Awaits for Gilead Sciences Stock. Stay Invested.

Dow Jones
·
Oct 02

Legend Biotech Director Makes Bold Move With Fresh Insider Stock Sale

TIPRANKS
·
Oct 02

Legend Biotech Director Corazon D. Sanders Sells 27,370 Shares for $258,920.20

Reuters
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Oct 02

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Oct 02

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

Gilead Sciences Announces Dividend of R$ 0.2394442440 Per Unit for Brgildbdr 000

Reuters
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

Legend Biotech Launches Inaugural Elite Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma

THOMSON REUTERS
·
Oct 01

Vir Biotechnology Names Aziz Sawaf as CFO Effective Oct. 5, 2026

Reuters
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01